Charles River Laboratories International (CRL)

As of 30 September 2026, short interest in CRL is 2,878,537 shares, up 343,484 shares over the last month. Over the last 48 readings it ranged from 1,851,902 shares (31 October 2024) to 4,666,350 shares (15 April 2026). At the reported average volume of 1.1M shares a day that is 2.7 days to cover.

<iframe src="https://xoomar.com/embed/stocks/crl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of CRL volume is 71.2%, up 13.6 points over the last five sessions. Over the last 30 readings it ranged from 21.4% (31 August 2026) to 73.6% (6 October 2026). The latest reading sits at the top of that range. The latest reading is 19.0 points above the 30-session average of 52.2%, on 293K shares reported.

As of 9 September 2026, the fails-to-deliver balance in CRL is 227 shares, up 222 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (17 June 2026) to 81,156 shares (30 June 2026). The latest reading sits at the bottom of that range.

Over the last 90 days CRL insiders reported 1 open-market buy ($3K) against 18 sells ($26.0M), so the dollar flow leans toward selling. Latest filing: Parisotto Shannon M (CEVP, Disc & Safety Assessment) on 2026-10-05.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

11 Form 144 notices on file for CRL worth $42.9M at the prices reported; 10 in the last 90 days worth $26.0M. Latest: Parisotto Shannon M filed on 2026-10-05 to sell 981 shares ($309K) from 2026-10-05.

5 holders report 5% or more of CRL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.2% of the class (4,865,628 shares), filed 2026-09-08 for an event on 2026-08-31.

5 of the 30 tracked managers held CRL at their latest 13F, $398.4M in total at quarter-end prices. Citadel Advisors is the largest at $270.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-27) Charles River Laboratories International reported revenue of $1.00B, down 2.7% from the same quarter a year earlier, and net loss of $1.5M (-0.03 diluted EPS). In FY 2025 it generated $737.6M of operating cash flow and spent $360.7M on buybacks.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-27; shares outstanding as of 2026-07-25 from the cover page.